APHINITY | European Journal of Cancer

APHINITY | European Journal of Cancer

OVERVIEW Nearly half of patients in the APHINITY trial were overweight/obese. Overweight/obesity was associated with poorer survival outcomes. Higher chemotherapy discontinuation rates were found in patients with overweight/obesity. Obesity remained linked to poorer...
Navigating the biopharma services landscape

Navigating the biopharma services landscape

BIO-Europe Spring 2025 Panel: ‘On-trend strategies: Navigating the biopharma services landscape’   On the first day of the BIO-Europe Spring event in Milan, BioXconomy’s Editor Millie Nelson hosted a lively panel on “Navigating the biopharma services landscape”....
ALTTO | ESMO Open

ALTTO | ESMO Open

OVERVIEW Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. The final 10-year analysis of the ALTTO trial is presented here. study details The Adjuvant...